Streetbeat News

Products Services

FRLN

Freeline Therapeutics will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201 gene therapy candidate for Gaucher Disease Type 1 at the European Society of Gene & Cell Therapy Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:18 am

CLSD

Clearside Biomedical presented data from the OASIS and extension study at the Retina Society 56th Annual Scientific Meeting. The results highlight the benefits of Clearside's patented suprachoroidal delivery platform and its lead drug candidate, CLS-AX (axitinib injectable suspension), developed for the treatment of neovascular age-related macular degeneration.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:16 am

AAPL

Apple Inc. plans to introduce a new in-store system that allows iPhones to receive essential software updates before they are unboxed. The system involves a proprietary 'pad-like device' in Apple Stores, which will wirelessly activate the iPhone, apply the necessary software update, and power off the device without opening the packaging. The company aims to roll out this system to its stores before the end of the year.

Portfolio Pulse from Ananya Gairola

October 16, 2023 | 11:15 am

OLMA

Olema Oncology has announced that the Phase 2 clinical results of Palazestrant for metastatic breast cancer will be presented at the 2023 ESMO Congress.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:14 am

TNXP

Tonix Pharmaceuticals has completed the clinical phase of the Phase 2 UPLIFT1 study of TNX-601 ER, a potential treatment for Major Depressive Disorder. The topline results from the intention-to-treat sample are expected in early November 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:13 am

NCNA

NuCana presented data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. The drug has been well tolerated both as a monotherapy and in combination with pembrolizumab, showing signs of efficacy including tumor volume reductions and prolonged time on treatment.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:12 am

OMGA

Omega Therapeutics has announced new preclinical data for OTX-2101, a potential treatment for non-small cell lung cancer. The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The treatment is being tested in combination with immune checkpoint inhibitors or EGFR inhibitors.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:11 am

META

Meta Platforms Inc. (NASDAQ:META) has introduced two new features to its Threads platform: an edit button and voice threads. The edit feature allows users to correct their posts within a five-minute window, while voice threads provide a new mode of interaction. These features are part of Meta's strategy to improve Threads and compete with Twitter, which charges users for post-editing.

Portfolio Pulse from Rounak Jain

October 16, 2023 | 11:09 am

IKT

Inhibikase Therapeutics has released an analysis of eleven unblinded participants from the 201 trial evaluating Risvodetinib (IKT-148009) in untreated Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:09 am

TLSA

Tiziana Life Sciences has reported six-month data showing clinical improvements in non-active secondary progressive multiple sclerosis patients treated with Foralumab. The improvements were related to Modified Fatigue Impact Scale scores and similar clinical measures of physical function.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:02 am